A Phase 2, International, Multicenter, Open-label Clinical Trial of Subcutaneous Tbo-Filgrastim in Pediatric Patients With Solid Tumors Undergoing Myelosuppressive Chemotherapy
Federman, N., Dragomir, M. D., Kizyma, Z., Roganovic, J., Bias, P., Lammerich, A. ... Buchner, A. (2019). A Phase 2, International, Multicenter, Open-label Clinical Trial of Subcutaneous Tbo-Filgrastim in Pediatric Patients With Solid Tumors Undergoing Myelosuppressive Chemotherapy. Journal of Pediatric Hematology/Oncology, 41. (7), 525-531. doi: 10.1097/mph.0000000000001542
Federman, Noah, et al. "A Phase 2, International, Multicenter, Open-label Clinical Trial of Subcutaneous Tbo-Filgrastim in Pediatric Patients With Solid Tumors Undergoing Myelosuppressive Chemotherapy." Journal of Pediatric Hematology/Oncology, vol. 41, no. 7, 2019, pp. 525-531. https://doi.org/10.1097/mph.0000000000001542
Federman, Noah, Monica D. Dragomir, Zoryana Kizyma, Jelena Roganovic, Peter Bias, Andreas Lammerich, Zipi R. Ben Arie, Linglong Zou, Gerald Hoehn and Anton Buchner. "A Phase 2, International, Multicenter, Open-label Clinical Trial of Subcutaneous Tbo-Filgrastim in Pediatric Patients With Solid Tumors Undergoing Myelosuppressive Chemotherapy." Journal of Pediatric Hematology/Oncology 41, no. 7 (2019): 525-531. https://doi.org/10.1097/mph.0000000000001542
Federman, N., et al. (2019) 'A Phase 2, International, Multicenter, Open-label Clinical Trial of Subcutaneous Tbo-Filgrastim in Pediatric Patients With Solid Tumors Undergoing Myelosuppressive Chemotherapy', Journal of Pediatric Hematology/Oncology, 41(7), pp. 525-531. doi: 10.1097/mph.0000000000001542
Federman N, Dragomir MD, Kizyma Z, Roganovic J, Bias P, Lammerich A, and sur.. A Phase 2, International, Multicenter, Open-label Clinical Trial of Subcutaneous Tbo-Filgrastim in Pediatric Patients With Solid Tumors Undergoing Myelosuppressive Chemotherapy. Journal of Pediatric Hematology/Oncology [Internet]. 2019 [cited 2024 August 28];41(7):525-531. doi: 10.1097/mph.0000000000001542
N. Federman, et al., "A Phase 2, International, Multicenter, Open-label Clinical Trial of Subcutaneous Tbo-Filgrastim in Pediatric Patients With Solid Tumors Undergoing Myelosuppressive Chemotherapy", Journal of Pediatric Hematology/Oncology, vol. 41, no. 7, pp. 525-531, 2019. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:771828. [Accessed: 28 August 2024]